VCE-004.8 is a new cannabidiol derivative that reduces fibrosis
Fibrosis is a pathological feature of most chronic inflammatory diseases. Fibrosis is defined by the excessive accumulation of fibrous connective tissue (such as collagen and fibronectin) in and around inflamed or damaged tissue, which can lead to permanent scarring, organ malfunction and, ultimately, death, as seen in end-stage liver disease, kidney disease, idiopathic pulmonary fibrosis and heart failure.
Among fibrotic diseases, VivaCell is focused on Systemic Sclerosis or Scleroderma. Scleroderma is a rare diseases characterized by vasomotor disturbances; fibrosis; subsequent atrophy of the skin, subcutaneous tissue, muscles, and internal organs (eg, alimentary tract, lungs, heart, kidney, CNS); and immunologic disturbances accompany these findings.
Cannabinoids are attractive therapeutic agents against fibrosis since they target both PPARγ and CB2 receptors. They represent attractive targets because of its potential role in modulating inflammatory and fibrotic responses (Reviewed by Dantas et al., 2015; Akhmetshina et al., 2009).
Since VCE-004.8 is a dual PPARγ/CB2 agonist, nowadays it is in a R&D program to evaluate its promising potential as therapeutic agent for Systemic Sclerosis.